ATAI Life Sciences B.V.* ATAI 深 沪
等待开盘 08-01 09:30:00 美东时间
4.215
+0.745
+21.47%
华盛通- 最 高4.22
- 今 开3.70
- 成交量 989.69万股
- 最 低 3.655
- 昨 收 3.47
- 总市值 8.89亿
- 52周最高 4.22
- 市盈率 静 --
- 换手率 4.69%
- 52周最低 1.03
- 委 比 -85.15%
- 总股本 2.11亿
- 历史最高 22.91
- 量 比 2.72
- 振 幅 16.28%
- 历史最低 1.025
- 每 手 1
- 风险率 0.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多精神健康成医药并购新风口！传艾伯维(ABBV.US)正洽谈收购Gilgamesh 估值或达10亿美元
据知情人士透露，艾伯维正在洽谈收购专注于精神健康治疗的Gilgamesh Pharmaceuticals。如果交易成功，将增强艾伯维在精神疾病治疗方面的产品管线。
07-31 08:52
美股大行评级 | 微软获上调目标价最高至570美元；摩根大通维持网易"超配"评级，目标价升至140美元
今日重点评级关注：Leerink Partners：维持Celcuity"跑赢大市"评级，目标价从28美元升至60美元；Macquarie：维持Churchill Downs"跑赢大市"评级，目标价从150美元升至155美元
07-29 09:30
Market-Moving News for July 28th
CELC: 133% | Celcuity Released Topline Results From PIK3CA Wild-Type Cohort Of Phase 3 VIKTORIA-1 Trial Of Gedatolisib Plus Fulvestrant With And Without Palbociclib Versus Fulvestrant In Advanced Breast
07-28 19:36
Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia
<p>A Phase 2b clinical trial evaluating inidascamine for cognitive impairment associated with schizophrenia did not meet its primary endpoint, though showed numerical improvements in cognitive and functional measures. The drug exhibited a favorable safety profile with no evidence of sedation, weight gain, or extrapyramidal symptoms. Full data analysis, including secondary endpoints and subgroup analyses, is ongoing to explore potential responder ...
07-25 20:05
'California Governor He's 'All In' On Psychedelic Therapy Access, But Worries About Capitalists Commercializing It' - Marijuana Moment
https://www.marijuanamoment.net/california-governor-hes-all-in-on-psychedelic-therapy-access-but-worries-about-capitalists-commercializing-it/
07-21 22:21
美股大行评级 | 潜在涨幅336.36%！Canaccord Genuity上调ATAI Life Sciences目标价至12美元，维持"买入"评级
Redburn Atlantic：下调Adobe(ADBE)评级至"卖出"，目标价从420美元降至280美元
07-03 11:01
美股牛股 | Wolfspeed单日暴涨98%！拟进行破产重组；BitMine公告以太坊储备计划
Wolfspeed单日暴涨98%！拟通过破产重组削减约70%的债务；BitMine隔夜大涨幅35.7%，公告以太坊储备计划>>
07-02 19:38
atai Life Sciences raises $50M in private financing
atai Life Sciences (NASDAQ:ATAI) has announced a $50M private placement financing. The company entered into subscription agreements related to the purchase of 18,264,840 ordinary shares and pre-funded...
07-01 18:13
atai Life Sciences Announces $50 Million Private Placement Financing
atai Life Sciences announced a $50 million financing led by Ferring Ventures and Apeiron Investment Group, with participation from Ally Bridge Group and ADAR1. The funds will be used for clinical development and corporate purposes. The private placement is subject to closing conditions, including expiration of the Hart-Scott-Rodino waiting period. The financing is expected to close in Q3 2025. atai aims to advance its psychedelic-based therapies ...
07-01 10:05
atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression
The Phase 2b clinical trial of BPL-003, an intranasal mebufotenin, achieved primary and secondary endpoints in treating treatment-resistant depression (TRD). Both 8 mg and 12 mg doses showed significant and durable reductions in depressive symptoms compared to a low-dose control, with rapid onset and favorable tolerability. The study, involving 193 patients across six countries, supports advancing the 8 mg dose to Phase 3. Companies atai Life Sci...
07-01 10:00
